Rallybio (RLYB) Projected to Post Quarterly Earnings on Thursday

Rallybio (NASDAQ:RLYB) is expected to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Rallybio to post earnings of ($1.04) per share and revenue of $0.10 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 17, 2026 at 12:30 PM ET.

Rallybio Stock Down 7.1%

NASDAQ RLYB opened at $10.00 on Wednesday. The firm has a 50-day moving average price of $6.05 and a two-hundred day moving average price of $5.37. Rallybio has a 12-month low of $1.76 and a 12-month high of $11.49. The company has a market capitalization of $52.80 million, a P/E ratio of -3.91 and a beta of -1.13.

Institutional Trading of Rallybio

Several institutional investors have recently modified their holdings of the business. Citadel Advisors LLC boosted its position in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares in the last quarter. Susquehanna International Group LLP raised its position in Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after acquiring an additional 2,996 shares in the last quarter. Renaissance Technologies LLC increased its stake in Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after buying an additional 120,892 shares during the last quarter. Finally, XTX Topco Ltd increased its position in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the last quarter. Institutional investors own 90.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Rallybio in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Rallybio has a consensus rating of “Reduce” and an average target price of $40.00.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.